Relmada Therapeutics (RLMD) Other Operating Expenses (2012 - 2022)

Relmada Therapeutics (RLMD) reported Other Operating Expenses of $6.4 million for Q2 2022, up 878407.05% quarter-over-quarter from $723.0 in Q1 2013.

Relmada Therapeutics (RLMD) Other Operating Expenses (2012 - 2022) Analysis & Trends

Relmada Therapeutics (RLMD) has 3 years of Other Operating Expenses data on file, last reported at $6.4 million in Q2 2022.

Other Operating Expenses for Q2 2022 came in at $6.4 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2023 was $6.4 million (changed N/A YoY), and the FY2022 annual result was $6.4 million, changed N/A from the prior year.
Other Operating Expenses rose to $6.4 million in Q2 2022 per RLMD's latest filing, from $723.0 in the prior quarter.
Over five years, Other Operating Expenses peaked at $6.4 million in Q2 2022 and troughed at $6.4 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Relmada Therapeutics	581.07 Mn	581.07 Mn	-

Download Data